Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
High Dose Chemotherapy Prolongs Survival for Leukemia
Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E
Past Highlights
Results:
1 -10 of 840
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
1.
A Study of Xeloda (Capecitabine) in Women With HER2-Negative Metastatic Breast Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase IV
Treatment
Closed
18 and over
Pharmaceutical / Industry
ML18527
NCT00121836
Last Modified:
11/1/1995
2.
Phase II/III Randomized Study of a New Paclitaxel Formulation Given by 3-Hour vs 96-Hour Infusion in Women with Refractory Metastatic Breast Cancer (Summary Last Modified 11/95)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III, Phase II
Treatment
Closed
any age
Other
MAOP-1195
NCI-V95-0749
Last Modified:
12/1/1995
3.
Phase III Study of a 3-Hour Infusion of a New Paclitaxel Product in Refractory Ovarian Cancer, with a Phase II Crossover to a 96-Hour Infusion at Progression (Summary Last Modified 12/95)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III, Phase II
Treatment
Closed
18 and over
Other
MAOP-7195
NCI-V95-0750
Last Modified:
5/31/2007
 
First Published:
7/1/1999
4.
Phase II/III Randomized Study of Paclitaxel and Carboplatin With or Without SCH 58500 in Patients with Newly Diagnosed Stage III Ovarian Epithelial or Primary Peritoneal Cancer With No Greater Than 2 cm Residual Disease Following Surgery (Summary Last Modified 07/2001)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III, Phase II
Treatment
Completed
18 and over
Pharmaceutical / Industry
SPRI-C/I98-102
SPRI-C98-102, NCI-V99-1544, NCT00003880
Last Modified:
6/20/2008
 
First Published:
9/1/2000
5.
Phase II/III Randomized Study of Paclitaxel and Carboplatin With or Without BMS-275291 in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III, Phase II
Treatment
Closed
18 and over
Pharmaceutical / Industry
CAN-NCIC-BR18
BMS-CA161-003, NCT00006229, BR18
Last Modified:
6/3/2008
 
First Published:
7/1/2001
6.
Phase II/III Randomized Study of Paclitaxel and Carboplatin With or Without Bevacizumab in Patients With Advanced, Metastatic, or Recurrent Non-Squamous Cell Non-Small Cell Lung Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III, Phase II
Treatment
Closed
18 and over
NCI
ECOG-4599
CALGB-E4599, E4599, NCT00021060
Last Modified:
5/10/2007
7.
Phase II/III Randomized Trial of DOX vs TAX vs DOX/TAX/G-CSF in Patients with Metastatic Breast Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III, Phase II
Treatment
Completed
any age
NCI
E-1193
NCCTG-923252, SWOG-9332, E-10292, E1193
Last Modified:
5/20/2008
 
First Published:
10/21/2005
8.
Phase II/III Randomized Study of Paclitaxel and Carboplatin With Versus Without AZD2171 in Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III, Phase II
Treatment
Closed
18 and over
Other, Pharmaceutical / Industry
CAN-NCIC-BR24
ZENECA-CAN-NCIC-BR24, NCT00245154, BR24, FHCRC-6107, UWCC-UW 6107, UWCC- 06-2707-H/B
9.
Weekly Taxol Plus Xeloda® vs Taxotere q3wk Plus Xeloda® in the Treatment of Metastatic BC
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III, Phase II
Treatment
Completed
18 and over
Other
NBCG10
REK 378-04-03133, NMA 03-07568, NCT00201435
10.
A Phase II Trial Neoadjuvant Paclitaxel and Cisplatin in Patients With Locally Advanced Head and Neck Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III, Phase II
Treatment
Completed
18 to 75
Pharmaceutical / Industry
CA139-384
NCT00337532
Select All on One Page
1
2
3
4
Next >
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute